Every S-3 that Agenus Inc. (AGEN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow AGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGEN filings page.
Agenus Inc. (AGEN) has filed a resale shelf registration covering up to 221,525 shares of common stock for selling stockholders. This includes 217,775 shares issuable upon exercise of amended A, B, C and new D warrants at $3.25 per share, generally expiring on June 25, 2031.
Agenus will not sell shares itself under this prospectus and will receive cash only if the warrants are exercised. Common shares outstanding were 45,161,916 as of September 8, 2026. The company remains a clinical-stage immuno-oncology developer with a $2.14 billion accumulated deficit and an auditor going-concern explanatory paragraph.
Agenus Inc. has filed a shelf registration statement covering the potential resale by selling securityholders of up to 77,976,718 shares of common stock. This includes 1,626,015 shares already issued, 21,409,212 shares issuable upon exercise of pre-funded warrants, and 54,941,491 shares issuable upon exercise of Series A and Series B purchase warrants issued in a July 2026 private placement.
The company will not receive proceeds from any resale of shares by the selling securityholders, but will receive cash if the warrants are exercised, which it currently expects to use for general corporate and working capital purposes. Agenus had 45,009,670 shares of common stock outstanding as of July 31, 2026, and its stock last traded at $7.49 per share on August 6, 2026. The company is a clinical-stage biotechnology firm focused on immuno-oncology, with lead program botensilimab alone and in combination with balstilimab, and it recently completed an approximately $85 million private placement that created the registered securities.
Agenus Inc., a clinical-stage immuno-oncology company, has filed a resale registration covering up to 2,133,333 shares of common stock previously issued to Zynext Ventures USA LLC under a June 2025 Securities Purchase Agreement. The shares were originally sold in a private strategic investment at $7.50 per share for an aggregate purchase price of approximately $16.0 million, with the transaction closing on January 15, 2026.
The registration allows the holder and its permitted transferees to resell these shares over time, but does not require any sales. Agenus will bear registration expenses and will not receive any proceeds from any resale of these shares. As of July 17, 2026, common shares outstanding were 44,752,288. The company focuses on antibody-based cancer immunotherapies, led by botensilimab and balstilimab, and holds a $24.3 million equity stake in MiNK Therapeutics plus a majority interest in vaccine adjuvant subsidiary SaponiQx.
Research and development expenses were $79.3 million in 2025 and $11.8 million for the quarter ended March 31, 2026. Agenus has incurred substantial cumulative losses, with an accumulated deficit of $2.18 billion as of December 31, 2025. Its auditor’s report includes an explanatory paragraph stating that recurring losses and net capital deficiency raise substantial doubt about the company’s ability to continue as a going concern.